Placement Agent on Korro Bio’s $85.0MM Private Placement

Oppenheimer & Co. Inc. acted as a Placement Agent on Korro Bio’s $85.0MM Private Placement

Korro Bio, Inc. (Korro) (Nasdaq: KRRO), a biopharmaceutical company developing a new class of genetic medicines based on editing RNA for rare and highly prevalent diseases, today announced it has entered into a subscription agreement for a private investment in public equity (PIPE) financing that is expected to result in gross proceeds of approximately $85 million to the Company, before placement agent fees and offering expenses.

The PIPE financing was led by Venrock Healthcare Capital Partners, and participation from new and existing investors, including ADAR1 Capital Management, Affinity Asset Advisors, Balyasny Asset Management, Driehaus Capital Management, Kalehua Capital, Lynx1 Capital Management, Nantahala Capital, and New Enterprise Associates.

The net proceeds from the PIPE financing, together with Korro’s unaudited cash, cash equivalents and marketable securities of $85.2 million as of December 31, 2025, will extend Korro’s cash runway into the second half of 2028 and advance its pipeline of potentially transformational therapies for genetic diseases being discovered by OPERA®, the Company’s novel RNA editing platform, with the remainder used for working capital and general corporate purposes. The PIPE funds clinical development milestones for key pipeline assets including clinical data for KRRO-121 and Korro’s GalNAc-conjugated alpha-1 antitrypsin deficiency (AATD) program, subject to regulatory filings. In addition, the funding enables the advancement of Korro’s longevity and liver health program targeting activation of the AMPKγ1 pathway.

Healthcare Life Sciences Investment Banking